Novo Nordisk Letter to the Bleeding Disorders Community on COVID-19

Industry News
The following is a letter provided by Novo Nordisk.

 “You’ve come to know us as a part of the fabric of the hemophilia community for more than 30 years, always working to make things better for everyone affected by rare bleeding disorders. 
We know this is a challenging time for all as with the World Health Organization (WHO) declaring a Public Health Emergency of International Concern (PHEIC) in response to the 2019-nCoV (novel coronavirus) outbreak. We especially recognize that this serious health crisis could leave you with uncertainty and concern. Know that we are here to extend our support to those affected by this situation. 
During the global coronavirus outbreak, Novo Nordisk’s key priority is to safeguard the continued supply of our lifesaving medicines to patients. We want to assure patients and health care providers we do not foresee a disruption in our ability to supply the US market with our hemophilia medicines. We have an inventory policy that helps ensure long-term supply. This is important since our medicines are needed every day by patients all over the world. 
We’ll continue monitoring this outbreak to ensure proper actions are taken as the situation unfolds. And if you have any questions, please call us at (800) 727-6500.”